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Case report
A 37-year-old female was admitted with a 3-month 
history of fatigue, progressive exertion dyspnoea and
left shoulder pain. Chest X-ray revealed a large pul-
monary process in the left hemi-thorax. One month
before  she  underwent  cardiac  catheterisation, and
severe  pulmonary  arterial  hypertension  was  diag-
nosed with a mean pulmonary artery pressure of 75
mmHg.There were no signs of coronary or valvular
heart disease.
At the age of 15 months she had a biopsy-proven
spindle cell soft tissue sarcoma in the posterior medi-
astinum. Because of chest wall invasion a resection
could not be performed, and she received percuta-
neous thoracic radiation with a total dose of 40 Gy.
In 1998, she underwent hysterectomy for a benign
myoma, and an uterus duplex and a vagina subsepta
were  found. In  addition, she  was  diagnosed  for
primary amenorrhoea.
On examination the patients height was 155 cm.
She had a  hypoplastic  left  hemi-thorax  and mam-
mary gland, most likely as a result of the radiation
therapy in childhood. Auscultation revealed dullness
and rales over the base of the left lung. A 4/6 systolic
cardiac murmur on the left parasternal was present.
Laboratory examinations were within normal limits.
Pulmonary function tests showed a severe restric-
tive pattern (TLC 2.6 l; [56% predicted]), but capil-
lary blood gases were normal (pCO2 5.8 kPa, pO2
10.3 kPa). Diffusion capacity was impaired, with a
transfer  factor  for  carbon  monoxide  of  53%
predicted, consistent  with  restrictive  lung  disease.
Pulmonary  scintigraphy  showed  a  highly  reduced
perfusion of the left lung with a distribution of 8% on
the left and 92% on the right lung, but no signs of
pulmonary embolism.
Thoracic  MRI  revealed  a  10 ´ 7 ´ 5cm  lesion
extending to the pericardium,the diaphragm and the
thoracic wall without signs of in￿ ltration (Fig. 1).
There were no focal lesions detected on abdominal
ultrasound, bronchoscopy, skeletal scintigraphy and
liver MRI.
Ultrasound-guided  transthoracic  biopsy  of  the
tumour revealed a malignant sarcoma.
The patient underwent left pneumonectomy with
partial  resection  of  the  diaphragm  and  the  peri-
cardium due to tumour adhesion. Intraoperatively,
a  patent  ductus  Botalli  (PDA)  was  found  and 
subsequently occluded.
Histology  revealed  a  pleomorphic  myogenic
sarcoma of the lung neither in￿ ltrating the pleura nor
metastasising  into  the  hilar  or  mediastinal  lymph
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Abstract
We describe a patient who underwent thoracic radiation therapy for biopsy-proven pulmonary spindle cell sarcoma in the
left lower lobe, 15 months after birth.At the age of 37 she developed shoulder pain, fatigue, and progressive exertion dysp-
noea. Chest X-ray revealed a pulmonary mass in the left lower lobe due to a cytology-proven malignant tumour.The patient
underwent  left  pneumonectomy. Histology  revealed  a  myosarcoma  of  the  lung, similar  to  the  previous  sarcoma.
Furthermore, the patient was diagnosed to have Turner syndrome mosaic and chromosomal analysis revealed a transloca-
tion t(1;13) in 3/50 metaphases. However a germline mutation of the p53 tumour suppressor gene was excluded. After 2
years of follow-up the patient is stable and there are no signs of recurrence of the tumour.We conclude a re-occurrence of
this very rare malignant disorder of the lung after a 36-year interval in a patient with Turner syndrome mosaic. Following
initial curative radiation therapy, with a remission over 36 years, lung resection was now successfully performed.
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DOI: 10.1080/1357714021000066395nodes (stage  I, Table  1; Fig. 2). Immunohistology 
was positive for vimentin, desmin, a -sarcomere actin
and  anti-muscle  actin  and  negative  for  a -smooth
muscle  actin. The  proliferation  rate  was  nearly 
60%.
A germline p53 mutation was excluded by auto-
mated sequencing of exons 4–10 of the TP 53 gene
(ABI 377,Perkin-Elmer®). Chromosomal analysis of
peripheral  blood  revealed  an  abnormal  karyotype
with a mosaic 45,X/46,XX,t(1;13)(p36;q14)/46,XX,
consistent  with  a  cytogenetic  variant  of  Turner
syndrome.
The further hospital stay was without complica-
tions. One month postoperatively, pulmonary artery
pressure had decreased to 60 mmHg by echocardio-
graphy. At  2-year  follow-up, the  patient  remained
stable without radiological signs of recurrence of the
tumour. Pulmonary  artery  pressure  further
decreased to 35 mmHg by echocardiography.
Discussion
Rhabdomyosarcoma  is  a  typical  extracranial  solid
malignant  tumour  presenting  during  childhood.
Every year,approximately 250 cases are diagnosed in
the  United  States. In  Germany, 60–70  cases  are
found  annually  with  an  incidence  of  0.5%.2,3 An
intrathoracic manifestation of RMS is very rare.4
Surgical  resection  is  the  only  curative  therapy.
Radiation  therapy  is  indicated  in  microscopic  or
residual disease, whereas chemotherapy is suggested
for  cytoreduction  and  eradication  of  micrometas-
tases. Multimodality  treatment  protocols, used  in
clinical  studies, enable  disease-free  survival  up  to
70%, in cases with incomplete resection.2,5 At recur-
rence of the sarcoma, 5-year survival is 40% for stage
I versus 3% for any higher stage.6
In  our  patient, radiation  therapy  of  inoperable
sarcoma during childhood induced complete remis-
sion  and  cure  from  the  malignant  disease  for  36
years.7
At the reoccurrence of the myosarcoma the patient
presented  with  localized  disease. The  tumour  was
completely  resected, and  there  was  no  indication 
for further anticancer therapy. Left pneumonectomy
was feasible despite the impaired pulmonary function,
because the  left  lung contributed only 8%  to  pul-
monary blood ￿ ow and oxygenation.8 However,there
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Fig. 1. MRI presents an approximately 10 ´ 7 ´ 5cm lesion
extending to the pericardium, the diaphragm and the thoracic
wall, without signs of in￿ ltration of the tumour. Furthermore,
there is a hypoplasia of the left hemithorax and a dilatation of
the right heart.
Fig. 2. Histology reveals an undifferentiated spindle cell like
sarcoma with multiple mitosis on the left side. On the right side
there is normal lung tissue with terminal bronchioles.
Table 1. Clinical group stage system for rhabdomyosarcoma (1)
Clinical group Extent of disease/surgical result
I A. Localized tumour, con￿ ned to site of origin, completely resected.
B. Localized tumour, in￿ ltrating beyond site of origin, completely resected.
II A. Localized tumour, gross total resection, but with microscopic residual disease.
B. Locally extensive tumour (spread to regional lymph nodes), completely resected.
C. Locally extensive tumour (spread to regional lymph nodes), gross total resection, but 
microscopic residual disease.
III A. Localized or locally extensive tumour, gross residual disease after biopsy only.
B. Localized or locally extensive tumour, gross residual disease after major resection 
(50% debulking).
IV A. Any size primary tumour, with or without regional lymph node involvement, with distant 
metastases, irrespective of surgical approach to primary tumour.1
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was a considerable perioperative risk because of the
severe pulmonary arterial hypertension. Surgical clo-
sure of the PDA was feasible after exclusion of an
Eisenmenger syndrome resulting in a postoperative
reduction of the pulmonary artery pressure.
We regard the present tumour as a re-occurrence
of a similar tumour type in a high-risk constellation
rather  than  a relapse after 36  years. Myosarcomas
have a high local recurrence rate, and both the recent
and the childhood tumour showed close histological
similarities. Furthermore, chromosomal analysis was
consistent with a variant of Turner syndrome. This
condition is associated with a higher rate of nongo-
nadal  malignancies.9,10 Our  Turner  syndrome-
affected patient had the following clinical anomalies:
short in stature (155 cm), primary infertility, heart
defect  (persistent  ductus  Botalli), hypoplastic  left
hemi-thorax  and  mammary  gland. There  were  no
signs  like  epicanthal  folds, low  nuchal  hair  line,
shield-like chest, webbed neck, high arched palate,
renal anomalies, pigmented nevi or lymphedema.
The  previous  radiation  therapy  could  also  be
regarded as a risk factor for developing a secondary
malignancy.11,12 However, a p53 germline mutation,
often  found  in  early  childhood  mesenchymal
tumours, was not present in our patient.13, 14
Conclusion
We report the successful lung resection of a re-occur-
ring pulmonary myosarcoma in a patient with Turner
syndrome.A previous radiation therapy resulted in a
complete remission for 36 years.The condition of an
earlier myosarcoma, previous radiation therapy, and
Turner syndrome has to be regarded as a high risk
constellation for a secondary malignancy.
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